Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF–TIMI 48
暂无分享,去创建一个
E. Antman | R. Giugliano | E. Braunwald | R. Cappato | J. Blanc | M. Mercuri | F. Nordio | S. Wiviott | C. Ruff | Thomas A. Zelniker | H. Lanz
[1] F. Lee,et al. Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects , 2013, Clinical pharmacology in drug development.
[2] Deepak L. Bhatt,et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.
[3] M. Lettino,et al. Inhibitors of propagation of coagulation: factors V and X. , 2011, British journal of clinical pharmacology.
[4] G. Lip,et al. Edoxaban: a focused review of its clinical pharmacology. , 2014, European heart journal.
[5] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[6] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[7] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.
[8] P Smith,et al. The effect of warfarin on mortality and reinfarction after myocardial infarction. , 1990, The New England journal of medicine.
[9] T. H. Oo,et al. Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence , 2015, Advances in hematology.
[10] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[11] S. Kleinman,et al. Equivalent inpatient mortality among direct-acting oral anticoagulant and warfarin users presenting with major hemorrhage. , 2019, Thrombosis research.
[12] E. Antman,et al. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. , 2016, The American journal of medicine.
[13] A. Algra,et al. Bleeding Increases the Risk of Ischemic Events in Patients With Peripheral Arterial Disease , 2009, Circulation.
[14] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[15] H. Arnesen,et al. Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.
[16] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[17] C. Albert,et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. , 2011, JAMA.
[18] G. Sanders,et al. Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation , 2018, Annals of Internal Medicine.
[19] David M Herrington,et al. Atrial fibrillation and the risk of myocardial infarction. , 2015, JAMA internal medicine.
[20] F R Rosendaal,et al. A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.
[21] Paul Burton,et al. Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.
[22] M. Keltai,et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. , 2013, International journal of cardiology.
[23] E. Antman,et al. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial , 2016, Journal of the American Heart Association.
[24] E. Antman,et al. A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial , 2017, European heart journal.
[25] J. Mendell,et al. Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers , 2011, Journal of clinical pharmacology.
[26] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[27] David A. Schoenfeld,et al. Partial residuals for the proportional hazards regression model , 1982 .
[28] Adrian V. Hernández,et al. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. , 2012, Archives of internal medicine.
[29] M. Pfeffer,et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.
[30] S. Yusuf,et al. Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial , 2012, Circulation.
[31] J. Alpert,et al. Universal definition of myocardial infarction. , 2007, European heart journal.
[32] G. Breithardt,et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. , 2014, European heart journal.
[33] J. Le Heuzey,et al. Response to letter regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study". , 2014, Circulation.
[34] M. Samama,et al. The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor , 2013, Journal of cardiovascular pharmacology.
[35] M. Fornage,et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.
[36] E. Antman,et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.
[37] E. Antman,et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial , 2015, The Lancet.
[38] H. White,et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. , 2009, Journal of the American College of Cardiology.
[39] G. Lip,et al. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? , 2010, American Journal of Medicine.
[40] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[41] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.